Ding Wang

5.8k total citations · 2 hit papers
134 papers, 3.6k citations indexed

About

Ding Wang is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ding Wang has authored 134 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Oncology, 37 papers in Molecular Biology and 35 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ding Wang's work include Cancer Immunotherapy and Biomarkers (27 papers), Lung Cancer Treatments and Mutations (12 papers) and Bladder and Urothelial Cancer Treatments (10 papers). Ding Wang is often cited by papers focused on Cancer Immunotherapy and Biomarkers (27 papers), Lung Cancer Treatments and Mutations (12 papers) and Bladder and Urothelial Cancer Treatments (10 papers). Ding Wang collaborates with scholars based in United States, China and France. Ding Wang's co-authors include James L. Gulley, Manish R. Patel, Jeffrey R. Infante, Alain Ravaud, Andrea B. Apolo, Carolyn D. Britten, Karen Kelly, Arnold B. Gelb, Kevin M. Chin and Alain C. Mita and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Journal of Neuroscience.

In The Last Decade

Ding Wang

122 papers receiving 3.5k citations

Hit Papers

Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In ... 2017 2026 2020 2023 2017 2017 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study
    2017 466 citations Ding Wang, Karen Kelly et al. profile →
  2. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial
    2017 429 citations Ding Wang, James L. Gulley et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ding Wang United States 28 1.8k 1.0k 898 889 563 134 3.6k
Frédéric Hollande Australia 37 1.5k 0.8× 1.9k 1.9× 676 0.8× 678 0.8× 365 0.6× 97 4.1k
Adriana Bajetto Italy 36 1.9k 1.1× 1.6k 1.6× 243 0.3× 1.4k 1.5× 266 0.5× 65 4.3k
Julie Guillermet‐Guibert France 26 956 0.5× 2.3k 2.3× 340 0.4× 469 0.5× 316 0.6× 53 3.9k
Mohd W. Nasser United States 35 983 0.6× 1.7k 1.7× 295 0.3× 752 0.8× 387 0.7× 72 3.5k
Jonathan A. Nowak United States 31 1.4k 0.8× 1.8k 1.8× 452 0.5× 681 0.8× 337 0.6× 100 4.4k
Sándor Paku Hungary 37 1.2k 0.7× 2.0k 2.0× 846 0.9× 276 0.3× 486 0.9× 131 4.4k
Guanjun Cheng United States 25 1.9k 1.1× 1.3k 1.3× 249 0.3× 2.7k 3.0× 501 0.9× 32 4.6k
Pieter In 'T Veld Belgium 38 825 0.5× 1.9k 1.9× 3.3k 3.6× 1.1k 1.3× 398 0.7× 101 6.5k

Countries citing papers authored by Ding Wang

Since Specialization
Citations

This map shows the geographic impact of Ding Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ding Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ding Wang more than expected).

Fields of papers citing papers by Ding Wang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ding Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ding Wang. The network helps show where Ding Wang may publish in the future.

Co-authorship network of co-authors of Ding Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Ding Wang. A scholar is included among the top collaborators of Ding Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ding Wang. Ding Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chen, Tiantian, Jirong Yang, Yaqin Tang, et al.. (2024). Label-free and highly sensitive detection of microRNA from cancer cells via target-induced cascade amplification generation of lighting-up RNA aptamers. Analytica Chimica Acta. 1289. 342187–342187. 6 indexed citations
2.
Xu, Xiaoling, Ding Wang, Weizhen Xu, et al.. (2024). NIPBL-mediated RAD21 facilitates tumorigenicity by the PI3K pathway in non-small-cell lung cancer. Communications Biology. 7(1). 206–206. 2 indexed citations
3.
4.
Xu, Xiaoling, Huihui Li, Mingying Xie, et al.. (2023). LncRNAs and related molecular basis in malignant pleural mesothelioma: Challenges and potential. Critical Reviews in Oncology/Hematology. 186. 104012–104012. 4 indexed citations
5.
Carducci, Michael A., Ding Wang, Matthias Bödding, et al.. (2023). A First-in-human, Dose-escalation Study of the Methionine Aminopeptidase 2 Inhibitor M8891 in Patients with Advanced Solid Tumors. Cancer Research Communications. 3(8). 1638–1647. 5 indexed citations
6.
Wang, Ding, et al.. (2023). Mitochondrial quality control in abdominal aortic aneurysm: From molecular mechanisms to therapeutic strategies. The FASEB Journal. 37(6). e22969–e22969. 7 indexed citations
7.
Simone, Charles B., Artur A. Serebrenik, Elizabeth Gore, et al.. (2023). Multicenter Phase 1b/2a Clinical Trial of Radioprotectant BIO 300 Oral Suspension for Patients With Non-Small Cell Lung Cancer Receiving Concurrent Chemoradiotherapy. International Journal of Radiation Oncology*Biology*Physics. 118(2). 404–414. 9 indexed citations
8.
9.
Li, Qiao, et al.. (2022). LAMP‐2A ablation in hippocampal CA1 astrocytes confers cerebroprotection and ameliorates neuronal injury after global brain ischemia. Brain Pathology. 33(2). e13114–e13114. 15 indexed citations
10.
Wang, Ding, et al.. (2022). Through network pharmacology and molecular docking to explore the underlying mechanism of Artemisia annua L. treating in abdominal aortic aneurysm. Frontiers in Physiology. 13. 1034014–1034014. 4 indexed citations
11.
Shanmugam, Gobinath, Ding Wang, Sellamuthu S. Gounder, et al.. (2020). Reductive Stress Causes Pathological Cardiac Remodeling and Diastolic Dysfunction. Antioxidants and Redox Signaling. 32(18). 1293–1312. 38 indexed citations
12.
Verschraegen, Claire F., Guy Jérusalem, Edward F. McClay, et al.. (2020). Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study. Journal for ImmunoTherapy of Cancer. 8(2). e001064–e001064. 19 indexed citations
13.
Wang, Ding, et al.. (2019). Characterization of TAG‐63 and its role on axonal transport in C . elegans. Traffic. 21(2). 231–249. 7 indexed citations
14.
Wang, Ding, et al.. (2019). The diagnostic value of serum CEA and CA19-9 in gastric stromal tumors. Zhonghua jianyan yixue zazhi. 42(2). 128–134. 1 indexed citations
15.
Xie, Yu, et al.. (2019). Serum cell-free DNA concentrations and integrity analysis of colorectal cancer patients before and after surgery. Cellular and Molecular Biology. 65(6). 44–51. 3 indexed citations
16.
Guan, Shanghui, Cong Wang, Xuan Chen, et al.. (2015). MiR-613: a novel diagnostic and prognostic biomarker for patients with esophageal squamous cell carcinoma. Tumor Biology. 37(4). 4383–4391. 21 indexed citations
17.
Wang, Ding, et al.. (2014). Levels of CD105+ cells increase and cell proliferation decreases during S-phase arrest of amniotic fluid cells in long-term culture. Experimental and Therapeutic Medicine. 8(5). 1604–1610. 12 indexed citations
18.
Wengrod, Jordan, Eleazar Vega‐Saenz de Miera, Ding Wang, et al.. (2013). PP6C Hotspot Mutations in Melanoma Display Sensitivity to Aurora Kinase Inhibition. Molecular Cancer Research. 12(3). 433–439. 30 indexed citations
19.
Chen, Weixian, Jun Zhang, Juan Zhang, et al.. (2011). Expression of the PreS1 Peptide of Hepatitis B Virus and Preparation of Its Polyclonal Antibody. Hybridoma. 30(6). 525–530. 3 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Frédéric Hollande Breakdown of academic impact, for papers by Adriana Bajetto Breakdown of academic impact, for papers by Julie Guillermet‐Guibert Breakdown of academic impact, for papers by Mohd W. Nasser Breakdown of academic impact, for papers by Jonathan A. Nowak Breakdown of academic impact, for papers by Sándor Paku Breakdown of academic impact, for papers by Guanjun Cheng Breakdown of academic impact, for papers by Pieter In 'T Veld
Rankless by CCL
2026